Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atea Pharmaceuticals Inc AVIR

Healthcare
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is... see more

Recent & Breaking News (NDAQ:AVIR)

ISS Recommends Aviragen Stockholders Vote AGAINST the Vaxart Merger on the CAS Group's BLUE Proxy Card

PR Newswire January 29, 2018

Aviragen Comments on ISS Report

GlobeNewswire January 26, 2018

Aviragen Therapeutics Issues Letter to Stockholders

GlobeNewswire January 24, 2018

CAS Group Delivers Letter to the Stockholders of Aviragen

PR Newswire January 24, 2018

Aviragen Board Of Directors Unanimously Recommends That Stockholders Vote FOR The Proposed Merger With Vaxart

GlobeNewswire January 11, 2018

Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir (BTA074) for the Treatment of Condyloma

GlobeNewswire November 29, 2017

Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results

GlobeNewswire November 2, 2017

Aviragen Therapeutics and Vaxart Enter into Merger Agreement

GlobeNewswire October 30, 2017